Efficacy, safety and tolerability of fesoterodine in asian patients with overactive bladder

Osamu Yamaguchi, Osamu Nishizawa, Masayuki Takeda, Masaki Yoshida, Myung Soo Choo, Jeong Gu Lee, Alex Tong-Long Lin, Ho Hsiung Lin, Wai Chun Andrew Yip, Hitoshi Isowa, Shintaro Hiro

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

To assess the efficacy, safety, and tolerability of fesoterodine 4 and 8 mg once daily (QD) compared with placebo in Asian subjects with overactive bladder (OAB) after 12 weeks of treatment. Methods: This phase II, dose-finding study consisted of a 2-week placebo run-in period followed by a 12-week, randomized, double-blind, placebo-controlled, treatment period. Eligible subjects were aged ≥20 years with ≥8 micturitions per 24 h and ≥1 urgency urinary incontinence (UUI) episodes per 24 h reported in a 3-day diary. The subjects were randomized to receive placebo, fesoterodine 4 mg, or fesoterodine 8 mg QD for 12 weeks. Results: Of 1232 subjects who entered the placebo run-in period, 951 received double-blind treatment. The mean number of UUI episodes per 24 h at baseline was 2.2 among the three treatment groups. The two fesoterodine groups showed statistically significant decreases from baseline in the mean number of UUI episodes per 24 h at week 12 (primary endpoint) compared with placebo. Most all-causality adverse events (e.g. dry mouth and constipation) were mild or moderate. The percentage of subjects with severe adverse events was low and similar among the treatment groups (placebo, 1.3%; fesoterodine 4 mg, 1.9%; fesoterodine 8 mg, 1.0%). Conclusion: Fesoterodine 4 and 8 mg QD were significantly better than placebo in improving OAB symptoms. Overall, the two fesoterodine dosing regimens were well tolerated. These results suggest that fesoterodine 4 and 8 mg QD are effective and well-tolerated treatments for OAB in Asian subjects.

Original languageEnglish
Pages (from-to)43-50
Number of pages8
JournalLUTS: Lower Urinary Tract Symptoms
Volume3
Issue number1
DOIs
Publication statusPublished - 2011 Apr 1

Fingerprint

Overactive Urinary Bladder
Safety
Placebos
Urinary Incontinence
Therapeutics
fesoterodine
Urination
Constipation
Causality
Mouth

Keywords

  • Fesoterodine
  • Overactive bladder
  • Randomized controlled trial

ASJC Scopus subject areas

  • Neurology
  • Urology

Cite this

Efficacy, safety and tolerability of fesoterodine in asian patients with overactive bladder. / Yamaguchi, Osamu; Nishizawa, Osamu; Takeda, Masayuki; Yoshida, Masaki; Choo, Myung Soo; Lee, Jeong Gu; Tong-Long Lin, Alex; Lin, Ho Hsiung; Andrew Yip, Wai Chun; Isowa, Hitoshi; Hiro, Shintaro.

In: LUTS: Lower Urinary Tract Symptoms, Vol. 3, No. 1, 01.04.2011, p. 43-50.

Research output: Contribution to journalArticle

Yamaguchi, O, Nishizawa, O, Takeda, M, Yoshida, M, Choo, MS, Lee, JG, Tong-Long Lin, A, Lin, HH, Andrew Yip, WC, Isowa, H & Hiro, S 2011, 'Efficacy, safety and tolerability of fesoterodine in asian patients with overactive bladder', LUTS: Lower Urinary Tract Symptoms, vol. 3, no. 1, pp. 43-50. https://doi.org/10.1111/j.1757-5672.2011.00091.x
Yamaguchi, Osamu ; Nishizawa, Osamu ; Takeda, Masayuki ; Yoshida, Masaki ; Choo, Myung Soo ; Lee, Jeong Gu ; Tong-Long Lin, Alex ; Lin, Ho Hsiung ; Andrew Yip, Wai Chun ; Isowa, Hitoshi ; Hiro, Shintaro. / Efficacy, safety and tolerability of fesoterodine in asian patients with overactive bladder. In: LUTS: Lower Urinary Tract Symptoms. 2011 ; Vol. 3, No. 1. pp. 43-50.
@article{1c4e1f3aa25645f5b24709a2d4304634,
title = "Efficacy, safety and tolerability of fesoterodine in asian patients with overactive bladder",
abstract = "To assess the efficacy, safety, and tolerability of fesoterodine 4 and 8 mg once daily (QD) compared with placebo in Asian subjects with overactive bladder (OAB) after 12 weeks of treatment. Methods: This phase II, dose-finding study consisted of a 2-week placebo run-in period followed by a 12-week, randomized, double-blind, placebo-controlled, treatment period. Eligible subjects were aged ≥20 years with ≥8 micturitions per 24 h and ≥1 urgency urinary incontinence (UUI) episodes per 24 h reported in a 3-day diary. The subjects were randomized to receive placebo, fesoterodine 4 mg, or fesoterodine 8 mg QD for 12 weeks. Results: Of 1232 subjects who entered the placebo run-in period, 951 received double-blind treatment. The mean number of UUI episodes per 24 h at baseline was 2.2 among the three treatment groups. The two fesoterodine groups showed statistically significant decreases from baseline in the mean number of UUI episodes per 24 h at week 12 (primary endpoint) compared with placebo. Most all-causality adverse events (e.g. dry mouth and constipation) were mild or moderate. The percentage of subjects with severe adverse events was low and similar among the treatment groups (placebo, 1.3{\%}; fesoterodine 4 mg, 1.9{\%}; fesoterodine 8 mg, 1.0{\%}). Conclusion: Fesoterodine 4 and 8 mg QD were significantly better than placebo in improving OAB symptoms. Overall, the two fesoterodine dosing regimens were well tolerated. These results suggest that fesoterodine 4 and 8 mg QD are effective and well-tolerated treatments for OAB in Asian subjects.",
keywords = "Fesoterodine, Overactive bladder, Randomized controlled trial",
author = "Osamu Yamaguchi and Osamu Nishizawa and Masayuki Takeda and Masaki Yoshida and Choo, {Myung Soo} and Lee, {Jeong Gu} and {Tong-Long Lin}, Alex and Lin, {Ho Hsiung} and {Andrew Yip}, {Wai Chun} and Hitoshi Isowa and Shintaro Hiro",
year = "2011",
month = "4",
day = "1",
doi = "10.1111/j.1757-5672.2011.00091.x",
language = "English",
volume = "3",
pages = "43--50",
journal = "LUTS: Lower Urinary Tract Symptoms",
issn = "1757-5664",
publisher = "Wiley Blackwell",
number = "1",

}

TY - JOUR

T1 - Efficacy, safety and tolerability of fesoterodine in asian patients with overactive bladder

AU - Yamaguchi, Osamu

AU - Nishizawa, Osamu

AU - Takeda, Masayuki

AU - Yoshida, Masaki

AU - Choo, Myung Soo

AU - Lee, Jeong Gu

AU - Tong-Long Lin, Alex

AU - Lin, Ho Hsiung

AU - Andrew Yip, Wai Chun

AU - Isowa, Hitoshi

AU - Hiro, Shintaro

PY - 2011/4/1

Y1 - 2011/4/1

N2 - To assess the efficacy, safety, and tolerability of fesoterodine 4 and 8 mg once daily (QD) compared with placebo in Asian subjects with overactive bladder (OAB) after 12 weeks of treatment. Methods: This phase II, dose-finding study consisted of a 2-week placebo run-in period followed by a 12-week, randomized, double-blind, placebo-controlled, treatment period. Eligible subjects were aged ≥20 years with ≥8 micturitions per 24 h and ≥1 urgency urinary incontinence (UUI) episodes per 24 h reported in a 3-day diary. The subjects were randomized to receive placebo, fesoterodine 4 mg, or fesoterodine 8 mg QD for 12 weeks. Results: Of 1232 subjects who entered the placebo run-in period, 951 received double-blind treatment. The mean number of UUI episodes per 24 h at baseline was 2.2 among the three treatment groups. The two fesoterodine groups showed statistically significant decreases from baseline in the mean number of UUI episodes per 24 h at week 12 (primary endpoint) compared with placebo. Most all-causality adverse events (e.g. dry mouth and constipation) were mild or moderate. The percentage of subjects with severe adverse events was low and similar among the treatment groups (placebo, 1.3%; fesoterodine 4 mg, 1.9%; fesoterodine 8 mg, 1.0%). Conclusion: Fesoterodine 4 and 8 mg QD were significantly better than placebo in improving OAB symptoms. Overall, the two fesoterodine dosing regimens were well tolerated. These results suggest that fesoterodine 4 and 8 mg QD are effective and well-tolerated treatments for OAB in Asian subjects.

AB - To assess the efficacy, safety, and tolerability of fesoterodine 4 and 8 mg once daily (QD) compared with placebo in Asian subjects with overactive bladder (OAB) after 12 weeks of treatment. Methods: This phase II, dose-finding study consisted of a 2-week placebo run-in period followed by a 12-week, randomized, double-blind, placebo-controlled, treatment period. Eligible subjects were aged ≥20 years with ≥8 micturitions per 24 h and ≥1 urgency urinary incontinence (UUI) episodes per 24 h reported in a 3-day diary. The subjects were randomized to receive placebo, fesoterodine 4 mg, or fesoterodine 8 mg QD for 12 weeks. Results: Of 1232 subjects who entered the placebo run-in period, 951 received double-blind treatment. The mean number of UUI episodes per 24 h at baseline was 2.2 among the three treatment groups. The two fesoterodine groups showed statistically significant decreases from baseline in the mean number of UUI episodes per 24 h at week 12 (primary endpoint) compared with placebo. Most all-causality adverse events (e.g. dry mouth and constipation) were mild or moderate. The percentage of subjects with severe adverse events was low and similar among the treatment groups (placebo, 1.3%; fesoterodine 4 mg, 1.9%; fesoterodine 8 mg, 1.0%). Conclusion: Fesoterodine 4 and 8 mg QD were significantly better than placebo in improving OAB symptoms. Overall, the two fesoterodine dosing regimens were well tolerated. These results suggest that fesoterodine 4 and 8 mg QD are effective and well-tolerated treatments for OAB in Asian subjects.

KW - Fesoterodine

KW - Overactive bladder

KW - Randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=79954615494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954615494&partnerID=8YFLogxK

U2 - 10.1111/j.1757-5672.2011.00091.x

DO - 10.1111/j.1757-5672.2011.00091.x

M3 - Article

AN - SCOPUS:79954615494

VL - 3

SP - 43

EP - 50

JO - LUTS: Lower Urinary Tract Symptoms

JF - LUTS: Lower Urinary Tract Symptoms

SN - 1757-5664

IS - 1

ER -